Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry

M. Frogel, C. Nerwen, A. Cohen, P. VanVeldhuisen, M. Harrington, M. Boron

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness. Study Design: Prospective observational registry enrolling those who received ≥1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites. Result: Of 19548 subjects enrolled, 40% were born before 32 weeks', 48% between 32 and 35 weeks' and 12% after 35 weeks' gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and > 2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates. Conclusion: Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.

Original languageEnglish (US)
Pages (from-to)511-517
Number of pages7
JournalJournal of perinatology : official journal of the California Perinatal Association
Volume28
Issue number7
DOIs
StatePublished - Jul 2008
Externally publishedYes

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Pediatrics, Perinatology, and Child Health

Fingerprint

Dive into the research topics of 'Prevention of hospitalization due to respiratory syncytial virus: Results from the Palivizumab Outcomes Registry'. Together they form a unique fingerprint.

Cite this